The job cuts include technical and scientific roles and follow multiple rounds of layoffs over the past 18 months.

The latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the ...

Genentech has executed another round of layoffs, eliminating 87 positions at its headquarters in South San Francisco. | Genentech has executed another round of layoffs, eliminating 87 positions at its ...

Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

Genentech is planning a massive overhaul of its 207-acre South San Francisco campus that could cost between $3B and $5B by ...

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

Oregon Governor Tina Kotek tours Genentech's Hillsboro facility, highlighting innovation and local talent development.

The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...

Genentech, the maker of cancer drug blockbusters Rituxan, Herceptin and Avastin, said Monday it would form a committee of independent directors to assess the offer.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall s.